Atelerix and JH Health Forge Powerful Middle East Partnership

In a strategic move that promises to reshape the biotech landscape in the Middle East, Atelerix, a UK-based biotech innovator, has entered into an exclusive partnership with Saudi Arabia’s JH Health Ltd. This collaboration grants JH Health exclusive rights to distribute Atelerix’s non-cryogenic cell preservation solutions in the region, bolstering local manufacturing and enhancing biobank capabilities.

Atelerix has been at the forefront of developing hydrogel encapsulation technology that extends the viability of biological samples at ambient temperatures, mitigating the challenges of traditional cryopreservation. Facing growing global demand, Atelerix has strategically partnered with regional experts to enhance its market reach, notably in pivotal regions like the Middle East, which is experiencing rapid growth in life sciences and healthcare. By aligning with JH Health, a key player in medical technology within Saudi Arabia, Atelerix will leverage local expertise to navigate regulatory requirements and establish vital distribution channels. This partnership not only marks a significant expansion for Atelerix but also opens doors to investment opportunities from Saudi sovereign funds.

The partnership between Atelerix and JH Health underscores a promising synergy of innovation and regional expertise, setting the stage for transformative advancements in cell preservation and transport. As Atelerix lays the groundwork for expanded operations in a burgeoning Middle Eastern market, this alliance exemplifies a strategic approach to global market expansion, promising notable contributions to biomedical research and logistics efficiencies in the region.